KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $512.9 million.

  • Biomarin Pharmaceutical's Long-Term Investments fell 872.76% to $512.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $512.9 million, marking a year-over-year decrease of 872.76%. This contributed to the annual value of $521.2 million for FY2024, which is 1470.98% down from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Long-Term Investments of $512.9 million as of Q3 2025, which was down 872.76% from $508.6 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's Long-Term Investments' 5-year high stood at $620.6 million during Q1 2024, with a 5-year trough of $321.1 million in Q1 2021.
  • For the 5-year period, Biomarin Pharmaceutical's Long-Term Investments averaged around $468.5 million, with its median value being $506.7 million (2025).
  • Its Long-Term Investments has fluctuated over the past 5 years, first crashed by 3425.77% in 2022, then skyrocketed by 8306.5% in 2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Long-Term Investments (Quarter) stood at $507.8 million in 2021, then plummeted by 34.26% to $333.8 million in 2022, then soared by 83.06% to $611.1 million in 2023, then fell by 14.71% to $521.2 million in 2024, then dropped by 1.59% to $512.9 million in 2025.
  • Its Long-Term Investments stands at $512.9 million for Q3 2025, versus $508.6 million for Q2 2025 and $506.7 million for Q1 2025.